Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study

OBJECTIVES: To evaluate real-world persistence and effectiveness of the IL-12/23 inhibitor, ustekinumab or a tumour necrosis factor inhibitor (TNFi) for psoriatic arthritis over 3 years. METHODS: PsABio (NCT02627768), a prospective, observational study, followed patients with PsA prescribed first-li...

Descripción completa

Detalles Bibliográficos
Autores principales: Gossec, Laure, Siebert, Stefan, Bergmans, Paul, de Vlam, Kurt, Gremese, Elisa, Joven-Ibáñez, Beatriz, Korotaeva, Tatiana V, Lavie, Frederic, Noël, Wim, Nurmohamed, Michael T, Sfikakis, Petros P, Sharaf, Mohamed, Theander, Elke, Smolen, Josef S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086293/
https://www.ncbi.nlm.nih.gov/pubmed/36600178
http://dx.doi.org/10.1136/ard-2022-222879

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086293/
https://www.ncbi.nlm.nih.gov/pubmed/36600178
http://dx.doi.org/10.1136/ard-2022-222879

Ejemplares similares